| -0.11 / -2.71%|
The 8 analysts offering 12-month price forecasts for Avanir Pharmaceuticals Inc have a median target of 7.50, with a high estimate of 13.00 and a low estimate of 4.00. The median estimate represents a +89.87% increase from the last price of 3.95.
The current consensus among 8 polled investment analysts is to Buy stock in Avanir Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.